PMID- 17119331
OWN - NLM
STAT- MEDLINE
DCOM- 20070222
LR  - 20220316
IS  - 0250-8095 (Print)
IS  - 0250-8095 (Linking)
VI  - 26
IP  - 5
DP  - 2006
TI  - Long-term erythropoietin therapy decreases CC-chemokine levels and intima-media 
      thickness in hemodialyzed patients.
PG  - 497-502
AB  - BACKGROUND: CC-chemokines are now widely accepted in the recruitment of 
      leukocytes from the blood compartment into tissues, and their role in the 
      progression of atherosclerosis has been documented. Recombinant human 
      erythropoietin (EPO) has become widely used to treat anemic HD patients. However, 
      little is known about the effect of EPO on the plasma CC-chemokine levels and 
      intima-media thickness (IMT) in HD patients. METHODS: Assessment of 
      CC-chemokines: monocyte chemoattractant protein-1 (MCP-1), macrophage 
      inflammatory proteins (MIP-1alpha, MIP-1beta), regulated upon activation, normal 
      T cell expressed and secreted (RANTES) and IMT were performed in 26 stable HD 
      patients and 15 healthy controls. The patients were divided into 3 groups: group 
      I (n = 8, without EPO), group II (n = 9, EPO at a mean dose of 76 +/- 48 
      U/kg/week for more than 4 months), and group III (n = 9, EPO at a mean dose of 
      110.5 +/- 21 U/kg/week for more than 12 months), none of them on iron therapy. 
      RESULTS: MCP-1, MIP-1alpha, MIP-1beta and IMT values were significantly higher, 
      whereas RANTES were significantly lower in HD patients without EPO therapy than 
      those in healthy controls. CC-chemokine levels were found to be significantly 
      lower in patients administered EPO when compared to subjects without EPO. In the 
      patients treated with EPO for more than 12 months IMT values were significantly 
      decreased compared to patients not receiving this hormone. CONCLUSION: These 
      results suggest that long-term EPO therapy decreased CC-chemokine and IMT values 
      in patients undergoing regular HD in the absence of concomitant iron 
      supplementation.
CI  - Copyright (c) 2006 S. Karger AG, Basel.
FAU - Pawlak, Krystyna
AU  - Pawlak K
AD  - Department of Nephrology and Clinical Transplantation, Medical University, 
      Bialystok, Poland. krystynapawlak@poczta.onet.pl
FAU - Pawlak, Dariusz
AU  - Pawlak D
FAU - Mysliwiec, Michal
AU  - Mysliwiec M
LA  - eng
PT  - Journal Article
DEP - 20061121
PL  - Switzerland
TA  - Am J Nephrol
JT  - American journal of nephrology
JID - 8109361
RN  - 0 (Chemokines, CC)
RN  - 11096-26-7 (Erythropoietin)
SB  - IM
MH  - Atherosclerosis/pathology/prevention & control
MH  - Carotid Arteries/*drug effects/pathology
MH  - Chemokines, CC/*antagonists & inhibitors/*blood
MH  - Erythropoietin/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Renal Dialysis
MH  - Tunica Intima/*drug effects/pathology
MH  - Tunica Media/*drug effects/pathology
MH  - Uremia/*blood/drug therapy/*pathology/therapy
EDAT- 2006/11/23 09:00
MHDA- 2007/02/23 09:00
CRDT- 2006/11/23 09:00
PHST- 2006/08/18 00:00 [received]
PHST- 2006/10/10 00:00 [accepted]
PHST- 2006/11/23 09:00 [pubmed]
PHST- 2007/02/23 09:00 [medline]
PHST- 2006/11/23 09:00 [entrez]
AID - 97269 [pii]
AID - 10.1159/000097269 [doi]
PST - ppublish
SO  - Am J Nephrol. 2006;26(5):497-502. doi: 10.1159/000097269. Epub 2006 Nov 21.